Trial Profile
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate; RIX 4414; Varicella zoster virus vaccine live
- Indications Chickenpox; Diphtheria; Haemophilus infections; Measles; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Rubella; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- 07 Feb 2022 Results published in the Vaccine
- 19 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Jan 2010 New trial record